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Abstract
OBJECTIVE: To investigate the effect of Xiaoaiping
Injection (XAP) on advanced hepatocellular carcino-
ma (HCC) in patients.
METHODS: Sixty-eight patients with advanced
HCC were assigned to a control group of 36 and a
treatment group of 32. The control group was treat-
ed with best supportive treatment (BST) and the
treatment group was given XAP plus BST. XAP was
administered daily by iv and the treatment course
was lasted for 30 days for both groups. The immedi-
ate therapeutic efficacy, Karnofsky performance sta-
tus (KPS) scores, and the changes in immunity indi-
cators (CD3+, CD4+ and CD8+ T cells) were measured
and compared before and after treatment. The pro-
gression-free survival (PFS) rate and overall survival
(OS) rate in the 2 groups were analyzed.
RESULTS: The immediate therapeutic efficacy and
KPS of the treatment group were better than those
in the control group (P<0.05). Patients in the treat-
ment group had higher percentages of CD3 and
CD4 T-lymphocytes in peripheral blood than those
in the control group (P<0.05). The median survival
time was 27.0 weeks in the treatment group and
24.5 weeks in the control group. The 6-months cu-
mulative survival rates in the treatment and control
groups were 33.3% and 25.0% , respectively, with
no significant difference (P>0.05). The PFS was 18
weeks in the treatment group and 15 weeks in con-
trol group (P<0.05).
CONCLUSION: XAP enhances the quality of life
(QOL) of patients with advanced HCC, improves
their immunity and extends their PFS.
© 2013 JTCM. All rights reserved.
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INRODUCTION
Hepatocellular carcinoma (HCC) is one of the most
common tumours. It is difficult to diagnose HCC at
its early stage due to its fast progress. When definitely
diagnosed, HCC usually has already developed to its
advanced stage. Moreover, the fatality rate of HCC is
very high, making it the third cause of cancer death.1
Conventional treatment for HCC include surgical re-
moval, liver transplant, ablation, chemoembolization
and molecular targeted therapy.2 However, none of
these methods is ideal due to various reasons. For exam-
ple, it is estimated the treatment with surgical removal
or radiofrequency ablation can only be offered to 10%
of HCC patients with smaller size of tumors.3 Addi-
tional reasons include innate or low specific immunity,
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high recurrence rate of the disease, poor efficacy of ra-
dioactive therapy and chemoembolization, and high
likelihood of intrahepatic spread and distant metasta-
sis. Due to these limitations of currently available surgi-
cal and oncological treatments and difficulties in early
diagnosis, there is an urgent need to find new efficient
therapies to treat advanced HCC. The current study is
aimed at identifying treatment options to prolong the
life span and to improve the quality of life (QOL) of
patients with advanced HCC.
Xiaoaiping is a traditional Chinese herbal medicine ex-
tracted from the roots of Marsdenia tenacissima mainly
found in Yunnan and Guizhou provinces of China. Ac-
cording to the theories of Traditional Chinese Medi-
cine, Marsdenia tenacissima, bitter and slightly sweet
in taste and cool in nature, an effective anticancer drug
acting on lung, stomach, and bladder channels, can
prevent certain poisons and relieve cough and asthma.4
Marsdenia tenacissima contains steroidal saponins, al-
kaloids, flavonoids, polysaccharides, resins, pigments
and other chemical constituents, some of which have
excellent antitumor activities.5 However, there are few
reports on basic and clinical researches addressing the
anticancer effects of Marsdenia tenacissima. Especially,
systematic research addressing its effect on the survival
rate of cancer patients is scarce. In this study, we saw a
promising effect of Xiaoaiping injection (XAP) on ad-
vanced HCC in 32 patients by measuring their progres-
sion-free survival (PFS) rate and Karnofsky perfor-
mance status (KPS) score.
MATERIALS ANDMETHODS
Patients
All patients signed a consent form according to the
Declaration of Helsinki. The study protocol was ap-
proved by the Ethics Committee of Fujian University
of Traditional Chinese Medicine. Patients diagnosed
with advanced HCC at our hospital from September
2009 to March 2011 (China Classification System ⅢA/
ⅢB) were included in this study. Patients who under-
went surgery and received or were receiving interven-
tional therapy were excluded. Diagnosis of HCC was
based on the level of serum alpha-fetoprotein (AFP≥
400 ng/mL), imaging of ultrasound (iU22, Philips
Healthcare, Bothell, WA, USA) and computed tomog-
raphy (Asteion multiple, Toshiba, Kawasaki, Japan), or
liver biopsy with AFP <400 ng/mL.6 Patients with a
KPS score ≥60 and an estimated life expectancy of >3
months were recruited in the study.
Sixty-eight subjects of advanced HCC were randomly
assigned to the treatment group and control group for
a single-blind clinical study. Among the 32 cases in the
treatment group were 23 males and 9 females aged 32
to 75 years, 49 years on average, 10 cases of portal vein
thrombosis and 30 cases of hepatitis B virus (HBV) in-
fection, 13 cases of massive type of tumour, 7 cases of
nodular type of tumour and 12 cases of diffuse type of
tumour, and 24 cases at grade A, 6 cases at grade B and
2 cases at grade C according to Child-Pugh's classifica-
tion.
Among the 36 cases in the control group were 26
males and 10 females aged 36 to 78 years, 51 years on
average, 15 cases of portal vein thrombosis and 33 cas-
es of HBV infection, 15 cases of massive type of tu-
mour, 4 cases of nodular type of tumour and 17 cases
of diffuse type of tumour, and 22 cases at grade A, 10
cases at grade B and 4 cases at grade C according to
Child-Pugh's classification.
There was no significant difference between the two
groups in age, gender and clinical stage.
Treatment
In the treatment group, while the patients were receiv-
ing BST including nutritional support, improving liver
function and relieving pain, intravenous drip was ad-
ministered with 40 mL of XAP (Sanhome Pharmaceu-
tical Co. Ltd., Nanjing, China) added to 250 mL of
5% glucose or normal saline, QD, for 30 consecutive
days as one therapeutic course. Another 30-day treat-
ment course was conducted after a 2-week interval. In
the control group, only BST was administered for 30
days.
Evaluation
Evaluation of immediate efficacy: before and after one
month of treatment, immediate efficacy was evaluated
according to response evaluation criteria in solid tu-
mors (RECIST)7 with ultrasonography or computed to-
mography. The efficacy is classified into 4 grades: com-
plete remission (CR), partial remission (PR), stable dis-
ease (SD) and progressive disease (PD). The total ef-
fective rate was calculated with the formula: [(Num-
ber of cases with CR+ PR + SD)/Total number of
cases] x 100%.
Assessment of general immune function
In order to evaluate the effect of XAP injection on gen-
eral immune function, CD3+, CD4+ and CD8+ T-lym-
phocyte counts before and after treatment were mea-
sured with flow cytometry (Becton Dickinson Calid,
Franklin Lakes, NJ, USA).
QOL of patients
KPS scoring is used to quantify the QOL of cancer
and other patients in terms of their general well-being
and activities of daily life.8 The pre-treatment and
post-treatmentKPS scores of both groupswere evaluated.
Survival rate
The primary and secondary end points for this study
were PFS and OS. PFS was defined as the interval
from the onset of treatment to disease progression or
death. OS was defined as the time from the date of di-
agnosis to date of death or the date of the last fol-
low-up visit. All patients were followed until death or
November 1, 2011.
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Adverse reactions
Adverse reactions due to XAP infusion, such as shiver-
ing, fever or allergy, were monitored and categorized in-
to different degrees of severity, 0-IV, according to the
World Health Organization (WHO) evaluation criteria
1998.9
Statistical analysis
Differences of enumeration data were evaluated with
Chi-square test and differences of measurement data
with t-test at a 95% confidence level. Survival analysis
was conducted with Kaplan-Meier and Long-rank
tests. The survival rate was calculated in terms of
weeks. All analyses were performed with SPSS 13.0
software (SPSS Inc, Chicago, IL, USA).
RESULTS
Immediate effect
The total effective rate was 71.8% in the treatment
group and 47.2% in the control group with significant
difference between the two groups (P=0.039) (Table 1).
Changes in immunity indicators
The percentages of CD3+, CD4+ and CD4+/CD8+ sub-
populations of T cells in the peripheral blood of the
two groups showed no significant differences before
treatment. After treatment, the percentages in the treat-
ment group were much higher than those in the con-
trol group (P<0.05) (Table 2).
Comparison of KPS scores
The pre-treatment KPS score was 63±6 in the control
group and 62±6 in the treatment group (P>0.05). Af-
ter treatment, the KPS score was 53± 9 in the control
group and 67±8 in the treatment group (P<0.05) (Fig-
ure 1).
OS rate
The median survival rate was (24.5 ± 1.4) weeks [95%
confidence interval (CI), 21.7-27.2 weeks] and
6-month cumulative survival rate is 25.0% in the con-
trol group. The median survival rate was (27.0 ± 2.4)
weeks [95% CI, 22.3-31.7 weeks] and 6-month cumu-
lative survival rate was 33.3% in the treatment group.
The survival curves (Figure 2) of the two groups were
not significantly different from one another by
Log-rank test.
Progression-free survival
The median PFS was (15.0 ± 1.1) weeks [95% CI,
12.9-17.1 weeks] in the control group and (18.0±2.0)
weeks [95% CI, 14.1-21.9 weeks] in the treatment
group. The PFS curve (Figure 3), of the treatment
Table 1 Comparison of immediate effect between two
groups (case)
Notes: CR: complete remission; PR: partial remission; SD:
stable disease; PD: progressive disease.
Group
Treatment
Control
CR
0
0
PR
2
0
SD
21
17
PD
9
19
Table 2 Changes in immune index before and after treatment between the two groups
Notes: BT: before treatment; AT: after treatment. aP<0.05,cP<0.01,comparison between before and after treatment in the same group; bP<
0.05, comparison between before and after treatment in the same group.
Group
Treatment
Control
Time
BT
AT
BT
AT
CD3+
58.36±6.36
62.24±5.41ab
57.69±5.74
58.12±6.15
CD4+
30.72±4.02
33.18±2.75ab
31.09±4.37
30.46±4.88
CD8+
24.61±4.52
18.53±3.93c
25.28±3.56
20.50±2.79
CD4+/CD8+
1.25±1.01
1.76±1.21cb
1.23±1.16
1.48±1.29
Figure 1 KPS scores before and after treatment in the two
groups
KPS: Karnofsky performance status.
Figure 2 OS curves in the two groups
OS: overall survival.
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group was significantly different from that in the con-
trol group by Log-rank test (P<0.05).
No toxic or side effects were found in the treatment.
DISCUSSION
Modern pharmacological studies have demonstrated
that XAP can not only prevent cultured cancer cells
from proliferation, such as Bel-7404, HepG2 and
SGC-7901 cells, and induce their differentiation, but
also improve the chemotherapy efficacy of 5-fluoroura-
cil (5-FU).10-13 In addition, XAP has minimal toxicity
to immune and hematopoietic stem cells. On the other
hand, XAP can improve the proliferation of T and B
lymphocytes.14 Moreover, XAP improved the sensitivity
of non-small-cell lung cancer (NSCLC) cells carrying
T790M or K-ras mutations to gefitinib.15 The promis-
ing anti-tumour effect of XAP in vitro encourage fur-
ther study to explore its potential as an anti-cancer
medication.
The chemical composition of Marsdenia tenacissima
extract is complex. Studies have focused on the C21 ste-
roidal glycosides, the main active substances.5,16 In addi-
tion, in chemical and pharmacological studies of XAP,
the relationship between its pharmacodynamic proper-
ties and clinical action is not very clear, and systematic,
multi-center clinical study on XAP are rare. In the ma-
jority of clinical studies, the main outcomes measured
were short-term effects, QOL and immune function,17,18
but the survival rate of the patients was seldom ad-
dressed.
This study showed that the SD rate (as an indicator of
immediate efficacy) in the treatment group was signifi-
cantly higher than that in the control group, indicating
that XAP might inhibit tumour growth in clinical set-
ting. There was a significant difference between the
KPS scores in the two groups, indicating that XAP
could significantly improve the QOL of advanced
HCC patients. Most patients have an improvement in
appetite, quality of sleep, intensity of pain and abdomi-
nal distension.
Chronic hepatitis B virus infection is a main cause of
HCC. There are different functional immune deficien-
cies in patients with HCC, indicating reduction in
CD3+ and CD4+ T lymphocytes, an increase in CD8+
T lymphocytes, and a decrease in the CD4 +/CD8 + T
lymphocyte ratio.19 These changes reduce the immune
surveillance function, which in turn impairs the ability
of the immune system to inhibit the development of
tumours. In this study, the CD3+ and CD4+ T lympho-
cytes and the CD4+/CD8+ ratio in the treatment group
increased significantly after treatment, compared to the
corresponding values in the control group. There was
also an increase in the CD8+ lymphocytes. These data
demonstrated that XAP effectively alleviated the defi-
cits in immune function caused by the proliferation of
tumour cells in advanced HCC patients.
In our study, there was no difference in OS between
both groups, but PFS was 15 weeks in the control
group and 18 weeks in the treatment group (P<0.05).
3 weeks longer than that in the control group suggest-
ed XAP's clinical significance for the patients with ad-
vanced HCC.
In summary, the results of this study indicated that
XAP improved QOL, immune function, effectively in-
hibited further development of the cancer and delayed
disease progression, which suggests that XAP may be
an effective medication for patients with advanced
HCC.
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